Literature DB >> 17668647

Treatment of AIDS-associated anaplastic large-cell lymphoma with dose-adjusted EPOCH chemotherapy.

Nagaprasad Nagajothi1, Sandeep K Dham, Yevgeniy Gelfand, Jasotha Sanmugarajah.   

Abstract

Anaplastic large-cell lymphoma (ALCL) has rarely been described in patients with acquired immunodeficiency syndrome (AIDS). Reports of treatment of ALCL in the setting of AIDS are rare as well. Dose-adjusted EPOCH (DA-EPOCH; etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin) has been shown to be well tolerated and effective in the treatment of AIDS-related aggressive B-cell lymphomas. Treatment of AIDS-associated ALCL with DA-EPOCH has not been reported. This report describes two patients with AIDS-associated ALCL treated with DA-EPOCH chemotherapy. Both patients presented with advanced disease. Excellent clinical response was observed in both patients. The first patient completed six cycles of chemotherapy and remains in complete remission at 12 months of follow up. The second patient has received 2 cycles of chemotherapy thus far. She had an excellent response with rapid improvement of cutaneous disease and lymphadenopathy starting three days after the first cycle. Repeat imaging after two cycles of chemotherapy showed marked radiologic improvement as well. Chemotherapy was well tolerated by both patients. Our experience suggests that DA-EPOCH is an effective treatment for AIDS-associated ALCL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17668647      PMCID: PMC2574342     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  10 in total

Review 1.  CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.

Authors:  H Stein; H D Foss; H Dürkop; T Marafioti; G Delsol; K Pulford; S Pileri; B Falini
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

3.  Ki-1 positive large cell lymphoma. A morphologic and immunologic study of 19 cases.

Authors:  B A Agnarsson; M E Kadin
Journal:  Am J Surg Pathol       Date:  1988-04       Impact factor: 6.394

4.  Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma.

Authors:  R D Gascoyne; P Aoun; D Wu; M Chhanabhai; B F Skinnider; T C Greiner; S W Morris; J M Connors; J M Vose; D S Viswanatha; A Coldman; D D Weisenburger
Journal:  Blood       Date:  1999-06-01       Impact factor: 22.113

5.  Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.

Authors:  Richard F Little; Stefania Pittaluga; Nicole Grant; Seth M Steinberg; Mark F Kavlick; Hiroaki Mitsuya; Genoveffa Franchini; Martin Gutierrez; Mark Raffeld; Elaine S Jaffe; Gene Shearer; Robert Yarchoan; Wyndham H Wilson
Journal:  Blood       Date:  2003-02-27       Impact factor: 22.113

6.  A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy.

Authors:  Mark Bower; Brian Gazzard; Sundhiya Mandalia; Tom Newsom-Davis; Christina Thirlwell; Tony Dhillon; Anne Marie Young; Tom Powles; Andrew Gaya; Mark Nelson; Justin Stebbing
Journal:  Ann Intern Med       Date:  2005-08-16       Impact factor: 25.391

7.  CD30 (Ki-1) positive anaplastic large cell lymphomas in individuals infected with the human immunodeficiency virus.

Authors:  A Chadburn; E Cesarman; J Jagirdar; M Subar; R N Mir; D M Knowles
Journal:  Cancer       Date:  1993-11-15       Impact factor: 6.860

8.  [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].

Authors:  Yu-Long Peng; Hui-Qiang Huang; Xu-Bin Lin; Zhong-Jun Xia; Yu-Hong Li; Wei Wang; You-Jian He; Zhan-He Pan; Wen-Qi Jiang; Zhong-Zhen Guan
Journal:  Ai Zheng       Date:  2004-08

9.  ALK gene products in anaplastic large cell lymphomas and Hodgkin's disease.

Authors:  H Herbst; J Anagnostopoulos; B Heinze; H Dürkop; M Hummel; H Stein
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

10.  Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity.

Authors:  M Shiota; S Nakamura; R Ichinohasama; M Abe; T Akagi; M Takeshita; N Mori; J Fujimoto; J Miyauchi; A Mikata; K Nanba; T Takami; H Yamabe; Y Takano; T Izumo; T Nagatani; N Mohri; K Nasu; H Satoh; H Katano; J Fujimoto; T Yamamoto; S Mori
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

  10 in total
  2 in total

1.  EPOCH regimen as salvage therapy for adult T-cell leukemia-lymphoma.

Authors:  Eo Toriyama; Yoshitaka Imaizumi; Hiroaki Taniguchi; Jun Taguchi; Jun Nakashima; Hidehiro Itonaga; Shinya Sato; Koji Ando; Yasushi Sawayama; Tomoko Hata; Takuya Fukushima; Yasushi Miyazaki
Journal:  Int J Hematol       Date:  2018-04-12       Impact factor: 2.490

2.  A case report of human immunodeficiency virus-associated anaplastic lymphoma kinase protein-negative anaplastic large cell lymphoma.

Authors:  Hiroaki Taniai; Norihiro Furusyo; Masayuki Murata; Fujiko Mitsumoto; Motohiro Shimizu; Kazuhiro Toyoda; Eiichi Ogawa; Mosaburo Kainuma; Kyoko Okada; Jun Hayashi
Journal:  Springerplus       Date:  2013-08-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.